top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Blood Pressure Monitoring Devices & Accessories Market is Booming Worldwide Scrutinized in New Research

0 votes
2 views

Blood Pressure Monitoring Devices & Accessories Market: Introduction

Transparency Market Research has published a new report titled, ‘Global Blood Pressure Monitoring Devices & Accessories Market’. According to the report, the global blood pressure monitoring devices & accessories market was valued at ~US$ 1.9 Bn in 2018 and is projected to expand at a CAGR of ~7% from 2019 to 2027.

The medical term for high blood pressure is hypertension. Blood pressure is considered to be normal under a systolic value of 140 mmHg and under a diastolic value of 90 mmHg. A blood pressure monitoring device reads blood pressure automatically based on variations in the volume of blood in the arteries. Systolic and diastolic are terms used to depict or interpret blood pressure. The blood pressure is measured in terms of millimeters of mercury (mmHg). The three stages of hypertension are prehypertension (from 120-139 over 80-90), stage 1 (from 140-159 over 90-99), and stage 2 (from 160 and above over 100 and above).

Blood Pressure Monitoring Devices & Accessories Market: Major Segments

In terms of device, the global blood pressure monitoring devices & accessories market has been segmented into sphygmomanometers, automatic blood pressure monitors, ambulatory blood pressure monitors, blood pressure transducers, and blood pressure instrument accessories. Sphygmomanometers have been categorized into mercury sphygmomanometers, aneroid sphygmomanometers, and digital sphygmomanometers. Blood pressure transducers has been classified into disposable and reusable.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1630

Blood pressure instrument accessories have been split into blood pressure cuffs, and bladders, bulbs, and valves. The automatic blood pressure monitors segment is projected to dominate the global market during the forecast period, owing to increase in usage in different types of surgeries for different indications. User-friendliness and safe application are the major advantages of these devices. The segment held significant share of the global blood pressure monitoring devices & accessories market in 2018. The automatic blood pressure monitors segment is anticipated to expand at a moderate CAGR between 2019 and 2027, owing to rise in surgeries and adoption rate of self-serving diagnostic tools.

Sphygmomanometers are the other most preferred blood pressure monitors, as these are cost-effective and offer accurate readings. Growth of the sphygmomanometers segment is likely to be stable owing to decline in usage of mercury sphygmomanometers, introduction of large number of aneroid sphygmomanometers in the market, and rise in digitalization in the readings of blood pressure monitors. The blood pressure transducers and blood pressure instrument accessories segments are anticipated to witness moderate growth during the forecast period. High accuracy of blood pressure transducers, increase in the geriatric population, and favorable trade regulations in the developing countries are the major factors expected to propel the blood pressure transducers and blood pressure instrument accessories segments during the forecast period.

Based on end user, the global blood pressure monitoring devices & accessories market has been divided into hospitals, ambulatory surgical centers, clinics, home care settings, and others. The home care settings segment captured the largest market share in 2018, owing to the availability of trained & qualified personnel and favorable reimbursement structure.

The segment is expected to expand at the highest CAGR during the forecast period, attributed to the miniaturization of devices and rise in need & demand for self-testing devices by patients. Increase in the geriatric population and improvements in healthcare facilities in developing countries are anticipated to propel the clinics segment during the forecast period. However, rise in need & demand for blood pressure kiosks at public places (gym, airports, colleges, etc.) and government funding to boost the production of blood pressure monitors are likely to augment the ambulatory surgical centers and others segments during the forecast period.

Buy Now Blood Pressure Monitoring Devices & Accessories Market Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1630&ltype=S

Blood Pressure Monitoring Devices & Accessories Market: Prominent Regions

North America held major share of the global blood pressure monitoring devices & accessories market in 2018. Highly structured health care industry, presence of key players, and growth strategies of these players are the major factors driving the market in the region. Rise in awareness about the benefits of surgeries and procedures and increase in healthcare expenditure also contribute to the growth of the market in North America.

Asia Pacific held the second largest share of the global blood pressure monitoring devices & accessories market in 2018. Growth of the blood pressure monitoring devices & accessories market in the region can be attributed to rise in prevalence of chronic diseases and well-developed healthcare sector in the region. The market in Asia Pacific is expected to grow at a rapid pace during the forecast period. Increase in number of people with cardiovascular diseases, product approvals, and rise in awareness about cardiovascular diseases are factors anticipated to fuel the growth of the blood pressure monitoring devices & accessories market in the region.

Blood Pressure Monitoring Devices & Accessories Market: Key Players

Key players are expanding their footprint to strengthen their positions in the global blood pressure monitoring devices & accessories market. Increase in population with hypertension offers lucrative opportunities to key players to increase their share in the blood pressure monitoring devices & accessories market. Hence, manufacturers are engaging in new product development, collaborations, and distribution to gain market share.

Leading players operating in the global blood pressure monitoring devices & accessories market include Omron Healthcare, Inc., Koninklijke Philips N.V., Schiller AG, American Diagnostic Corporation, SPENGLER, Spacelabs Healthcare, Withings SA, Welch Allyn, Inc., SunTech Medical, Inc., A&D Medical, and GE Healthcare.

More Trending Reports by Transparency Market Research –

ePharmacy Market: prnewswire.com/news-releases/epharmacy-market-to-reach-us128-billion-by-2023-transparency-market-research-560938961.html

Canada Home Healthcare Market: prnewswire.com/news-releases/canada-home-healthcare-market-set-to-reach-us1894-bn-by-the-end-of-2020-transparency-market-research-565741581.html

posted 4 days ago by Bella Watson

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

The global glioblastoma multiforme treatment market is anticipated to rise significantly owing to key players adopting competitive strategies such as merger and acquisitions for marketing. According to a report by Transparency Market Research, the key players in the global glioblastoma multiforme treatment are adopting strategies such as development of biological drugs that helps in reducing the side effects in the patients which are caused due to consuming chemotherapeutic agents and immunosuppressant along with multiple therapies.

The prominent players in the market are also collaborating with diagnostic laboratories so as to increase awareness level of the population in regards to the availability of options for treatment for the invasive diseases.

Some of the key players operating in the global glioblastoma multiforme market are Celldex Therapeutics, Inc., Abbvie, Inc., Brostol-Myers Squibb Co., F.Hoffman La Roche, and Exellixis, Inc. During 2013, F.Hoffman La Roche was the most efficient and promising source of glioblastoma multiforme treatment all because of “brain shuttle” which was the company’s novel drug delivery system.

Request PDF Sample of Glioblastoma Multiforme Treatment Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4807

The global glioblastoma multiforme treatment market is expected to rise at a healthy CAGR of 11.4% during the forecast period of 2014 to 2022. The global market is expected to attain a valuation of $US0.91 bn by the end of 2022. The global glioblastoma multiforme product segment is led by bevacizumab product and is expected to rise in demand during the forecast period as it is more efficient than temozolomide. Geographically, the glioblastoma multiforme treatment market is led by North America. This region is consuming larger share in the market is expected to dominate the global market during the forecast period.

Rise in Awareness Regarding Cancer and Novel Therapies to Boost Global Glioblastoma Multiforme Market

The global glioblastoma multiforme treatment market is rising rapidly owing to increasing geriatric population. Rise in awareness about the brain tumor itself is generating demand for the glioblastoma multiforme treatment market. Various organizations across the globe are spreading awareness about the introduction of novel therapies thus, boosting the growth of market. Rise of modern techniques for diagnosis and rapid development of drug delivery technologies are likely to supplement the growth of the market. Increasing support from government to conduct research and development across the globe is adding fuel to the market.

Development of healthcare infrastructure is one of the reasons for market growth. The unmet medical needs require desperate novel treatment strategies thus, generating demand for the market. The glioblastoma multiforme treatment pipeline include a mix of immunotherapy, small molecules, biological therapeutics and other types of therapeutics that makes it ideal for treatment of disease. Advanced introduced in molecular biology and gene technology also has the potential to provide lucrative novel possibilities for effective treatment of diagnosed patients.

Buy Now “Glioblastoma Multiforme Treatment Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=4807&ltype=S

Recurrence of Disease Likely to Hamper Market Growth

The global glioblastoma multiforme treatment market is anticipated to face certain restrains in the market that might hamper the growth of the market. The current FDA approved treatments are likely to cause neurotoxicity in patients which might stagger the growth of market. This treatment is not resistance against DNA modifying agents thus, hampering its growth in the market. The migration of malignant cells inside the adjacent brain tissues increasing the complexity of surgery is also affecting the market.

The treatment options lack efficiency as the mortality rate is characterized by rapid growth and poor survival rates. Survival rates of glioblastoma is 8.7% even after glioblastoma multiforme treatment being in the healthcare sector since last few years. The modalities have worked little to decrease the overall mortality rate of patients. Recurrence of the disease, invasiveness of GBM, and resistance of glioma stem cell against conventional modalities are other potential factors that will hamper the growth of the global glioblastoma multiforme treatment market.

0 votes

Blood Pressure Monitoring Devices & Accessories Market: Introduction

Transparency Market Research has published a new report titled, ‘Global Blood Pressure Monitoring Devices & Accessories Market’. According to the report, the global blood pressure monitoring devices & accessories market was valued at ~US$ 1.9 Bn in 2018 and is projected to expand at a CAGR of ~7% from 2019 to 2027.

The medical term for high blood pressure is hypertension. Blood pressure is considered to be normal under a systolic value of 140 mmHg and under a diastolic value of 90 mmHg. A blood pressure monitoring device reads blood pressure automatically based on variations in the volume of blood in the arteries. Systolic and diastolic are terms used to depict or interpret blood pressure. The blood pressure is measured in terms of millimeters of mercury (mmHg). The three stages of hypertension are prehypertension (from 120-139 over 80-90), stage 1 (from 140-159 over 90-99), and stage 2 (from 160 and above over 100 and above).

Blood Pressure Monitoring Devices & Accessories Market: Major Segments

In terms of device, the global blood pressure monitoring devices & accessories market has been segmented into sphygmomanometers, automatic blood pressure monitors, ambulatory blood pressure monitors, blood pressure transducers, and blood pressure instrument accessories. Sphygmomanometers have been categorized into mercury sphygmomanometers, aneroid sphygmomanometers, and digital sphygmomanometers. Blood pressure transducers has been classified into disposable and reusable.

Blood pressure instrument accessories have been split into blood pressure cuffs, and bladders, bulbs, and valves. The automatic blood pressure monitors segment is projected to dominate the global market during the forecast period, owing to increase in usage in different types of surgeries for different indications. User-friendliness and safe application are the major advantages of these devices. The segment held significant share of the global blood pressure monitoring devices & accessories market in 2018. The automatic blood pressure monitors segment is anticipated to expand at a moderate CAGR between 2019 and 2027, owing to rise in surgeries and adoption rate of self-serving diagnostic tools.

Request PDF Sample of Blood Pressure Monitoring Devices & Accessories Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1630

Sphygmomanometers are the other most preferred blood pressure monitors, as these are cost-effective and offer accurate readings. Growth of the sphygmomanometers segment is likely to be stable owing to decline in usage of mercury sphygmomanometers, introduction of large number of aneroid sphygmomanometers in the market, and rise in digitalization in the readings of blood pressure monitors. The blood pressure transducers and blood pressure instrument accessories segments are anticipated to witness moderate growth during the forecast period. High accuracy of blood pressure transducers, increase in the geriatric population, and favorable trade regulations in the developing countries are the major factors expected to propel the blood pressure transducers and blood pressure instrument accessories segments during the forecast period.

Based on end user, the global blood pressure monitoring devices & accessories market has been divided into hospitals, ambulatory surgical centers, clinics, home care settings, and others. The home care settings segment captured the largest market share in 2018, owing to the availability of trained & qualified personnel and favorable reimbursement structure.

The segment is expected to expand at the highest CAGR during the forecast period, attributed to the miniaturization of devices and rise in need & demand for self-testing devices by patients. Increase in the geriatric population and improvements in healthcare facilities in developing countries are anticipated to propel the clinics segment during the forecast period. However, rise in need & demand for blood pressure kiosks at public places (gym, airports, colleges, etc.) and government funding to boost the production of blood pressure monitors are likely to augment the ambulatory surgical centers and others segments during the forecast period.

Blood Pressure Monitoring Devices & Accessories Market: Prominent Regions

North America held major share of the global blood pressure monitoring devices & accessories market in 2018. Highly structured health care industry, presence of key players, and growth strategies of these players are the major factors driving the market in the region. Rise in awareness about the benefits of surgeries and procedures and increase in healthcare expenditure also contribute to the growth of the market in North America.

Asia Pacific held the second largest share of the global blood pressure monitoring devices & accessories market in 2018. Growth of the blood pressure monitoring devices & accessories market in the region can be attributed to rise in prevalence of chronic diseases and well-developed healthcare sector in the region. The market in Asia Pacific is expected to grow at a rapid pace during the forecast period. Increase in number of people with cardiovascular diseases, product approvals, and rise in awareness about cardiovascular diseases are factors anticipated to fuel the growth of the blood pressure monitoring devices & accessories market in the region.

Buy Now “Blood Pressure Monitoring Devices & Accessories Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1630&ltype=S

Blood Pressure Monitoring Devices & Accessories Market: Key Players

Key players are expanding their footprint to strengthen their positions in the global blood pressure monitoring devices & accessories market. Increase in population with hypertension offers lucrative opportunities to key players to increase their share in the blood pressure monitoring devices & accessories market. Hence, manufacturers are engaging in new product development, collaborations, and distribution to gain market share.

Leading players operating in the global blood pressure monitoring devices & accessories market include Omron Healthcare, Inc., Koninklijke Philips N.V., Schiller AG, American Diagnostic Corporation, SPENGLER, Spacelabs Healthcare, Withings SA, Welch Allyn, Inc., SunTech Medical, Inc., A&D Medical, and GE Healthcare.

More Trending Reports by Transparency Market Research –

Pulmonary Arterial Hypertension Market: globenewswire.com/news-release/2018/07/24/1541108/0/en/Pulmonary-Arterial-Hypertension-Market-to-reach-a-valuation-of-US-5-19-Bn-by-2020-Says-TMR.html

Autoimmune Disease Diagnostics Market: globenewswire.com/news-release/2018/12/07/1663722/0/en/Autoimmune-Disease-Diagnostics-Market-is-likely-to-reach-US-17-06-billion-by-2023-TMR.html

0 votes

The global wearable medical devices market was valued at approximately US$ 6.8 Bn in 2017. It is projected to expand at a compound annual growth rate (CAGR) of more than 17.0% from 2018 to 2026, according to a new report published by Transparency Market Research (TMR) titled ‘Wearable Medical Devices Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026’. Expansion of the health care industry, government initiatives, increase in health care expenditure, rise in product approvals, and increase in patient population are projected to augment the global market from 2018 to 2026.

North America and Europe are likely to account for a dominant share of the global wearable medical devices market, owing to the presence of key players in these developed regions as well as high rate of adoption of technologically advanced wearable medical devices in these regions. Development of health care infrastructure and high medical expenditure by governments in emerging economies, such as China and India, are likely to boost the wearable medical devices market in Asia Pacific at a CAGR of 18.8% from 2018 to 2026.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1733

Large number of innovators and early adopters to propel market

The wearable technology is trendy; most users who purchase such products are innovators and early adopters. Large population of innovators and early adopters in developed countries and increasing number of people in this group in developing countries are likely to drive the market. Rising number of sports and fitness enthusiasts are seeking new ways to monitor their health. These early adopters are more concerned about their health and fitness. Hence, demand for the wearable medical devices is rising among this group. Large portion of the population in the U.S. and Canada falls under the group of early adopters. This results in rapid market penetration of wearable medical devices in the region.

Increasing incidence of chronic pain and high population of diabetic patients

Demand for wearable medical devices such as transcutaneous electrical nerve stimulation (TENS) and pulsed electromagnetic field therapy (PEMF) devices has increased significantly due to a rise in the cases of chronic pain. According to IDF (international Diabetes Federation), about 415 million people suffered from diabetes worldwide in 2015. It also states that one out of eleven adults is a diabetic. Rising number of people are suffering from diabetes due to the increased intake of unhealthy diet, sedentary lifestyle, and obesity. This can lead to serious complications such as kidney failure, heart diseases, and stroke. Thus, health of such people needs to be monitored on periodically. This fuels the demand for glucose monitoring devices. Diabetic patients are also at a risk of premature death due to cardiovascular diseases. This generates the need for wearable devices that can allow continuous cardiovascular monitoring at home and in clinics.

Buy Now @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1733&ltype=S

High cost of devices may hamper market growth in emerging countries

Wearable medical devices are largely utilized for health applications, particularly by patients suffering from chronic conditions. These are also used by athletes in their daily sports and fitness related activities. However, the high price of these devices remains a major issue, especially in developing countries. Thus, high price acts as a major barrier in the adoption of wearable medical devices. The cost of wearable medical devices that are being marketed currently ranges from US$ 150 to US$ 1000; it could even be higher. Wearable medical devices can be considered an unnecessary luxury in most developing nations across the world. Industry experts suggest the expansion of the economy of these regions would lead to rise in market share in the near future. However, high price of these devices is likely to prove to be a challenge for the middle and low income groups in developing countries, considering the falling value of their currency.

Asia Pacific market to expand significantly

Countries in Asia Pacific, such as China, Japan, and India, have a large diabetic population. Companies such as Pancreum and Omnipod can target this population base to expand their market share. According to major studies conducted across the globe, people in Asia are at a higher risk of suffering from Type II diabetes. The diabetic population is expected to increase consistently in the next few decades. According to the International Diabetes Federation (IDF), more than 382 million people across the globe, currently, suffer from diabetes. Thus, the high prevalence of diabetes and improvement in economic conditions are anticipated to propel the wearable devices market in Asia Pacific.

Apple Inc., Xiaomi Technology Co., Ltd, and Fitbit, Inc. to lead market

The report also provides profiles of leading players operating in the global wearable medical devices market. They include Xiaomi Technology Co., Ltd, Samsung Electronics Co. Ltd., Fitbit, Inc., Garmin Corporation, Apple Inc., Huawei Technologies Co., Ltd., Polar Electro, OMRON Corporation, Activinsights Ltd., and VitalConnect. Increase in mergers & acquisitions, strategic collaborations, and new product launches are expected to drive the global market during the forecast period. Additionally, strong product portfolio, high brand recognition, and strong geographic presence are expected to boost the market during the forecast period.

0 votes

The global erythropoietin drugs market is prognosticated to demonstrate steady growth in coming years, as reported by Transparency Market Research (TMR). The competitive ecosystem features a highly consolidated environment, with vendors involved in different tactics to beat the rival players. Leading vendors in the global erythropoietin drugs market engage in several organic and inorganic growth strategies. Mergers and acquisitions are a popular initiative undertaken by vendors in order to gain momentum in the global market.

The improvement of distribution channels is expected to be focused on by vendors operating in the global erythropoietin drugs market. This is likely to encourage vendors to find more distributors in their supply chain system. This will further amplify competition among the market players.

Research and development activities play a pivotal role in this industry, and market vendors are anticipated to engage in application-specific research. The segment of biosimilars is expected to offer rich growth opportunity to vendors, with increased number of clinical trials and approvals. Under-penetrated market will be the focus of established vendors and market entrants, with the aim of expansions/launches.

Key vendors in the global erythropoietin drugs market are Johnson & Johnson, Amgen Inc., Biocon Ltd., F. Hoffmann-La Roche Ltd., and Pfizer, Inc.

Request a PDF Sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1856

According to TMR’s predictions, the global erythropoietin drugs market is prognosticated to rise at a 7.5% CAGR over the forecast period from 2017 to 2025, and projected to be worth US$19.3 bn by the end of the forecast period.

Based on the geographical segmentation, the global erythropoietin drugs market is expected to be dominated by North America. The region boasts of fee waivers, favorable reimbursement policies, and approval associated with the product, propelling the North America market. On the basis of drugs class, Epotin alfa is anticipated to remain dominant over the forecast period. This could be attributed to the high prevalence of renal failures and cancer, as the drug is majorly used in these instances.

Rising Incidence of Anemia to Drive Erythropoietin Drugs Market

Substantial economic stresses are amplified by anemia and also affect the quality of life. AS reported by the Center for Disease Control and Prevention (CDC), some 5.5 million ambulatory care patients suffer from anemia due to a nutritional deficiency, while the second most prevalent cause is chronic disease. Although anemia is a common disease symptom, it remains undiagnosed and undertreated, particularly for patients with chronic renal diseases (CRD) that are not dialyzed. Approximately 20 million people in the U.S. have CKD, 2-4 million of which have anemia. Thus, an increasing number of anemia patients are driving the global market for erythropoietin.

Buy Now “Erythropoietin Drugs Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1856&ltype=S

Introduction of Biosimilars to Emerge as Key Market Trend

In the global erythropoietin drugs market, major pharmaceutical companies such as Pfizer, Amgen, and Novartis have shifted dramatically from reference drugs to biosimilars. Biosimilars are comparatively easy to develop and cost-effective, and need less time than biologics for approval. These associated benefits are anticipated in the forecast period to promote segment growth.

Other factors contributing to his dominance include the presence of large patient populations and patent expiration of biologics. In addition, there has been an increase in the availability of some biosimilars in the market. Furthermore, the biosimilars segment is expected to gain traction with increased awareness and high spending on healthcare, opening up growth avenues in the global erythropoietin drugs market.

New Product Launches, Patent Expiration to Drive Erythropoietin Drugs Market

Darbepoetin-alfa has been developed by Amgen, Inc. as a new erythropotine drug marketed under the Aranesp brand name. This medicinal product is patented in the United States and expires in 2024. Darbepoetin-alfa is expected to be positive for its economy, improved efficiency and long half-life, in the future. This is a viable way to treat anemia caused by renal disease at the end of the stage. Research on new therapeutic fields for the application of darbepoetin-alfa is under way, which is expected to serve the global erythropoietin drugs market with substantial growth potential.

More Trending Reports by Transparency Market Research –

Pulmonary Arterial Hypertension Market: globenewswire.com/news-release/2018/07/24/1541108/0/en/Pulmonary-Arterial-Hypertension-Market-to-reach-a-valuation-of-US-5-19-Bn-by-2020-Says-TMR.html

Autoimmune Disease Diagnostics Market: globenewswire.com/news-release/2018/12/07/1663722/0/en/Autoimmune-Disease-Diagnostics-Market-is-likely-to-reach-US-17-06-billion-by-2023-TMR.html

0 votes

The global active pharmaceutical ingredients market was valued at US$ 162,000.0 Mn in 2017 and is projected to expand at a cumulative annual growth rate (CAGR) of 5.4% from 2018 to 2026, according to a new report published by Transparency Market Research (TMR) titled ‘Global Active Pharmaceutical Ingredients (API)- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2028.’ The report suggests that increase in the use of pharmaceuticals globally is estimated to boost the active pharmaceutical ingredients market between 2018 and 2026.

North America and Asia Pacific are projected to dominate the global market, owing an increase in the demand for efficient and effective management of APIs manufacturing, high health care IT budgets, and high adoption of accelerated regulatory review of innovative medicines. The market in Europe is projected to expand at a moderate growth rate of 5.0% during the forecast period. The active pharmaceutical ingredients market in Latin America is likely to expand at a moderate pace during the forecast period. Key factors driving the market in Brazil are rapid improvement in health care infrastructure and increase in purchasing power of the people. In addition, health care companies are striving to cut hospitalization costs while offering better services to patients in the country.

Request PDF Sample of Active Pharmaceutical Ingredients (API) Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1690

Increase in Government Prioritization of Biomedical Innovation Globally to Fuel Market

Governments across the world have prioritized biomedical innovation. Accelerated regulatory review by the FDA for innovative medicines boosts the global active pharmaceutical ingredients market. The FDA has approved more than 45 drugs in 2017. Drugs approved by the FDA are used for the treatment of relapsed or refractory acute lymphoblastic leukemia, relapsed breast cancer, moderate-to-severe plaque psoriasis, advanced or metastatic urothelial carcinoma, acute bacterial skin infections, Chagas disease, open-angle glaucoma or ocular hypertension, type 2 diabetes mellitus, and septic or other distributive shock.

Increase in the Incidence of Acute and Chronic Diseases Globally to Fuel Market

Rise in the prevalence of cancer, cardiovascular diseases, and diabetes; sedentary lifestyles; and a rise in the aging population are key factors driving the active pharmaceutical ingredients (API) market. As per the National Cancer Institute, in 2016, there were an estimated 15.5 million cancer survivors in the U.S.. The number of cancer survivors is expected to increase to 20.3 million by 2026. As per an EU government agency survey, almost 49 million people were living with cardiovascular disease in the EU in 2017. Lung cancer is the leading cause of cancer deaths in Asia Pacific. China alone accounts for more than 50% of all cancer cases in this region. Changes in lifestyle and socio-cultural factors are propelling the incidence of cervical cancer. Major countries affected by breast cancer in Asia Pacific are India, Thailand, and China.

The Dominant In-house API Manufacturing Segment is Estimated to Lose Market Share During the Forecast Period

The in-house API manufacturing segment includes the active pharmaceutical ingredients produced for the internal consumption of a pharmaceutical company. The revenue of the in-house API manufacturing segment has declined in the past few years due to outsourcing of API production. High degree of competition and reduced profitability are the key factors attributed to the increased preference for outsourcing API production over in-house API manufacturing.

Buy Now “Active Pharmaceutical Ingredients (API) Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1690&ltype=S

The Synthetic Chemical API Segment is Projected to Lead the Active Pharmaceutical Ingredients Market

Around 66.0% of the APIs currently available in the market constitute synthetic chemical APIs, popularly known as small molecules. Although the top-selling drugs are biologics, the number of these drugs is quite small as compared to the small molecule drugs. Currently, over 3,000 small molecule drugs are available in the market, which provides significant business opportunities for synthetic API production.

Anti-infective Drugs and Cardiovascular Drugs Lead the Market

In terms of therapeutic, the market has been categorized into anti-infective drugs, metabolic disorders drugs, cardiovascular drugs, oncology drugs, central nervous system drugs, respiratory diseases drugs and others. The anti-infective drugs segment is likely to account for a leading share of the market during the forecast period. Increase in the incidence of cardiovascular diseases is anticipated to fuel the cardiovascular drugs segment during the forecast period.

Asia Pacific Offers Significant Business Development Opportunity

North America and Asia Pacific accounted for a key share of the global active pharmaceutical ingredients market in 2017. The regions are likely to gain market share by the end of 2026. High adoption of biotech/biological APIs and government initiatives to promote innovative medicine have contributed to the leading share held by these regions in the global active pharmaceutical ingredients market. Asia Pacific is projected to be a highly attractive region of the active pharmaceutical ingredients market.

The market in Asia Pacific is projected expand at a high CAGR of over 6.0% during the forecast period, due to the significant scale of drug production in the region. China and India are part of top three countries globally in terms of drug volume production. The market in Latin America and Middle East & Africa is anticipated to expand at a moderate growth rate during the forecast period.

Key Trend of Acquisitions and Collaborations among Leading Players to Increase Geographic Presence

The report also provide profiles of leading players operating in global active pharmaceutical ingredients market. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Boehringer Ingelheim International GmbH., Merck & Co., Inc., Novartis AG, F. Hoffmann-La Roche Ltd., and Bayer AG are a few leading players operating in the global active pharmaceutical ingredients market. The companies account for a significant market share.

Companies operating in the market are aiming to increase their geographic presence by means of strategic acquisitions and collaborations with leading players in respective domains and geographies. In March 2018, Ardena Holding NV acquired ChemConnection, a leading contract manufacturer of novel active pharmaceutical ingredients and nanomedicines.

...